



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10/14/04 Signature: [Signature]
(Ginny Lundell)

Docket No.: COTH-P03-504
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hammond et al.

Application No.: 10/646985

Confirmation No.: 1147

Filed: August 21, 2003

Art Unit: 1636

For: METHODS FOR PRODUCING NUCLEIC
ACIDS LACKING 3'-UNTRANSLATED
REGIONS AND OPTIMIZING CELLULAR
RNA-PROTEIN FUSION FORMATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Those patents or publications in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in prior application number 09/910518, filed July 20, 2001 (now abandoned) and application number 09/374,962, filed August 16, 1999 (now U.S. Patent No. 6312927) and relied upon in this application for an earlier filing date under 35 U.S.C. 120.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. COTH-P03-504.

Dated: October 14, 2004

Respectfully submitted,

By 

Xuqiong Wu

Registration No.: 55,745

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/646985
				Filing Date	August 21, 2003
				First Named Inventor	Philip W. Hammond
				Art Unit	1636
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	COTH-P03-504

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	4,843,003	06-27-1989	Henikoff et al.	
	AB	5,627,024	05-06-1997	Maruyama et al.	
	AC	5,643,768	07-01-1997	Kawasaki	
	AD	5,658,754	08-19-1997	Kawasaki	
	AE	5,789,208	08-04-1998	Sharon	
	AF	5,849,878	12-15-1998	Cantor et al.	
	AG	5,965,133	10-12-1999	Cantor et al.	
	AH	5,985,575	11-16-1999	Wickens et al.	
	AI	6,214,553-B1	04-10-2001	Szostak et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 98/31700	07-23-1998	The General Hospital Corporation		
	BB	WO 99/51773	10-14-1999	Phylos, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	CAPECCHI and KLEIN, "Release Factors Mediating Termination of Complete Proteins," Nature 226:1029-1033 (1970)		
	CB	CAPECCHI, "Polypeptide Chain Termination In Vitro: Isolation of a Release Factor," Proc. Natl. Acad. Sci. 58:1144-1151 (1967)		
	CC	DRUGEON et al., "Eukaryotic Release Factor 1 (eRF1) Abolishes Readthrough and Competes with Suppressor tRNAs at all Three Termination Codons in Messenger RNA," Nucl. Acids Res. 25(12):2254-2258 (1997)		
	CD	FROLOVA et al., "A Highly Conserved Eukaryotic Protein Family Possessing Properties of Polypeptide Chain Release Factor," Nature 372:701-703 (1994)		
	CE	FROLOVA et al., "Eukaryotic Polypeptide chain Release Factor eRF3 is an eRF1- and Ribosome-Dependent Guanosine Triphosphatase," RNA 2:334-341 (1996)		
	CF	FROLOVA et al., "Mammalian Polypeptide Chain Release Factor and Tryptophanyl-tRNA Synthetase are Distinct Proteins," The EMBO Journal 12(10):4013-4019 (1993)		
	CG	HAMMOND et al., "In Vitro Selection and Characterization of Bcl-X _L -binding Proteins From a Mix of Tissue-specific mRNA Display Libraries," The Journal of Biological Chemistry 276(24):20898-20906 (2001)		
	CH	HIGUCHI, R., Using PCR to Engineer DNA," Stockton Press, Chapter 6, pgs. 61-70, 1989		
	CI	ILAN, J., "Release Factor Regulating Termination of Complete Protein in a Eukaryotic		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

9555042_1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/646985
				Filing Date	August 21, 2003
				First Named Inventor	Philip W. Hammond
				Art Unit	1636
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	COTH-P03-504

		Organism," J. Mol. Biol. 77:437-448 (1973)	
	CJ	KISSELEV and FROLOVA, "Termination of Translation in Eukaryotes," Biochem. Cell Biol. 73:1079-1086 (1995)	
	CK	MIYAMOTO-SATO et al., "Specific Bonding of Puromycin to Full-Length at the C-Terminus," Nucl. Acids Res. 28(5):1176-1182 (2000)	
	CL	NIEMEYER et al., "Oligonucleotide-Directed Self-Assembly of Proteins: Semisynthetic DNA - Streptavidin Hybrid Molecules as Connectors for the Generation of Macroscopic Arrays and the Construction of Supramolecular Bioconjugates," Nucl. Acid Res. 22:5530-5539 (1994)	
	CM	ROBERTS et al., "RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins," Proc. Natl. Acad. Sci. USA, 94:12297-12302, 1997	
	CN	ROBERTS, "Totally In Vitro Protein Selection Using mRNA-protein Fusions and Ribosome Display", Current Opinion In Chemical Biology 3:268-273 (1999)	
	CO	SINGER et al., "Libraries for Genomic SELEX," Nucl. Acids Res. 25(4):781-786 (1997)	
	CP	STANSFIELD et al., "Depletion in the Levels of the Release Factor eRF1 Causes a Reduction in the Efficiency of Translation Termination in Yeast," Mol. Microbiol. 20:1135-1143 (1996)	
	CQ	STANSFIELD et al., "The Products of SUP45 (eRF1) and SUP35 Genes Interact to Mediate Translation Termination in Saccharomyces Cerevisiae," The EMBO J. 14:4365-4373 (1995)	
	CR	Stratagene Cloning Systems, Product Catalog (1992)	
	CS	ZHOURLAVLEVA et al., "Termination of Translation in Eukaryotes is Governed by two Interacting Polypeptide Chain Release Factors, eRF1 and eRF3," The EMBO Journal 14:4065-4072 (1995)	
	CT	ZOZULYA et al., "Mapping Signal Transduction Pathways by Phage Display," Nature Biotech. 17:1193-1198 (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/646985

Attorney Docket No.: COTH-P03-504

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On October 14, 2004
Date

Signature

Ginny Blundell

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO SB/08a/b